# US 2021/0275541 A1 · Targeted epigenetic therapy against distal regulatory element of tgfb2 expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275541 A1
- Document ID: US20210275541A1
- Status: Published application
- Kind: A1
- Application number: 16/495,098
- Filed: 2018-03-16
- Published: 2021-09-09
- Earliest claimed: 2017-03-17
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Harry C. Dietz; Joseph Shin
- Web page: https://patentgrep.com/patent/US20210275541A1

## CPC

- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- A61K 38/55: Protease inhibitors
- C07K 14/495: Transforming growth factor [TGF]
- G01N 33/5023: {on expression patterns}
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- G01N 2333/495: Transforming growth factor [TGF]
- G01N 2800/20: Dermatological disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The instant disclosure provides methods and compositions for the diagnosis, treatment and prevention of a TGFβ2-associated disease, disorder and/or condition, including, e.g., Scleroderma, other fibrotic disease, grade 4 glioblastoma (GBM) and/or Primary Open-Angle Glaucoma (POAG). The disclosure further provides pharmaceutical compositions and kits for the diagnosis, treatment and prevention of TGFβ2-associated diseases, disorders and/or conditions.

## Claims

### Claim 1

A method for treating a subject having or at risk of developing a transforming growth factor β2-associated disease, disorder and/or condition comprising:
administering to the subject an effective amount of one or more agents that modulate transforming growth factor β2 (TGFβ2) expression by targeting an enhancer sequence distal to a TGFβ2 locus,
thereby treating the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the transforming growth factor β2-associated disease, disorder and/or condition is Scleroderma and/or a fibrotic disease.

### Claim 3 (depends on 2)

The method of claim 2, wherein the TGFβ-associated disease, disorder and/or condition is grade 4 glioblastoma (GBM) or Primary Open-Angle Glaucoma (POAG).

### Claim 4 (depends on 1)

The method of claim 1, wherein the one or more agents modulate activity of one or more molecules at the enhancer sequence and/or inhibit binding to the enhancer sequence and/or inactivate the enhancer functions and/or activities.

### Claim 5 (depends on 4)

The method of claim 4, wherein the one or more agents: increase histone deacetylase activity, inhibit histone acetyltransferase activity, inhibit BRD4 activity or combinations thereof, as compared to a normal control at the enhancer sequence.

### Claim 6 (depends on 5)

The method of claim 5, wherein the TGFβ2 enhancer sequence is Enhancer 4514 (chr1 218632917-218634115), variants or fragments thereof.

### Claim 7 (depends on 5)

The method of claim 5, wherein the agent that inhibits acylation of a TGFβ2 enhancer sequence or promotes deacetylation of a TGFβ2 enhancer sequence is an inhibitor of CBP/P300.

### Claim 8 (depends on 7)

The method of claim 7, wherein the inhibitor of CBP/P300 is selected from the group consisting of bromodomain inhibitor SGC-CBP30, C646, C375 and C146.

### Claim at position 9

9-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein the agent that inhibits acylation of a TGFβ2 enhancer sequence or promotes deacetylation of a TGFβ2 enhancer sequence is a histone deacetylase (HDAC).

### Claim 14 (depends on 5)

The method of claim 5, wherein an inhibitor of BRD4 is JQ1.

### Claim 15 (depends on 1)

The method of claim 1, further comprising an agent that modulates NF-κB activity.

### Claim 16 (depends on 14)

The method of claim 14, wherein the agent inhibits NF-κB activity.

### Claim 17

A method of identifying a candidate agent for treating a transforming growth factor β2-associated disease, disorder and/or condition comprising:
contacting a cell comprising an enhancer sequence which modulates transforming growth factor β2 (TGFβ2) expression with a candidate agent; and,
comparing expression levels of TGFβ2 with a normal control; wherein the candidate agent inhibits of TGFβ2 expression.

### Claim at position 15

18-20. (canceled)

### Claim 21 (depends on 1)

The method of claim 1 wherein the subject has a transforming growth factor β2-associated disease, disorder and/or condition.

### Claim 22 (depends on 21)

The method of claim 21, wherein a fibrotic synthetic repertoire (FSR) comprising one or more pro-fibrotic markers, is diagnostic of a transforming growth factor β2-associated disease, disorder and/or condition.

### Claim 23 (depends on 21)

The method of claim 21, wherein an FSR comprises expression of one or more markers comprising COL1A1, SERPINH1 or combinations thereof, and/or TGFβ2 expression.

### Claim 24 (depends on 21)

The method of claim 21, wherein the transforming growth factor β2-associated disease, disorder and/or condition is Scleroderma and/or a fibrotic disease.

### Claim at position 20

25-27. (canceled)

### Claim 28 (depends on 21)

The method of claim 21, wherein the TGFβ2 enhancer sequence is Enhancer 4514 (chr1 218632917-218634115), variants or fragments thereof.

### Claim 29

A method of treating a subject having transforming growth factor β2-associated disease, disorder and/or condition, comprising:
administering to the subject an isolated nucleic acid sequence encoding a gene-editing complex comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease and at least one guide RNA (gRNA), the gRNA being complementary to a target sequence in an enhancer distal to a transforming growth factor β2 (TGFβ2), wherein the gene editing complex normalizes expression of TGFβ2,
thereby treating the subject.

### Claim at position 23

30-33. (canceled)

### Claim 34

An isolated nucleic acid encoding: a guide nucleic acid, wherein the guide nucleic acid comprises a targeting nucleotide sequence directed to one or more target sequences in an enhancer distal to a transforming growth factor β2 (TGFβ2); a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease/Cas (CRISPR/Cas), comprising CRISPR/Cas tethered or conjugated to one or more modulators associated with TGFβ2 expression.

### Claim at position 25

35-37. (canceled)
